Document
type: Class

Anualidad
type: Class

Information Content Entity
type: Class

Continuant
type: Class

Conference Poster
type: Class

Entity
type: Class

Congress communication
type: Class

Generically Dependent Continuant
type: Class

2017
type: Class

RDF description of THE PROFILES OF PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO THEIR BELIEFS IN THEIR BIOLOGICAL DRUGS. ARCO STUDY - http://research.umh.es/vivo/pub/comunicacion/184783
type: Document
rights: termsOfUse
date: 2026-08-15T09:07:51
publisher: THE PROFILES OF PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO THEIR BELIEFS IN THEIR BIOLOGICAL DRUGS. ARCO STUDY

THE PROFILES OF PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO THEIR BELIEFS IN THEIR BIOLOGICAL DRUGS. ARCO STUDY
type: Entity
most specific type: 2017
related by: Autor:133301-Comunicación:184783
date time value: 184783 pubdate
type: Information Content Entity
type: Continuant
ARG_2000028: 184783 vcard
RO_0002353: EULAR ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY
type: Congress communication
type: Document
most specific type: Congress communication
page end: 551
type: 2017
type: Conference Poster
type: Thing
type: Generically Dependent Continuant
most specific type: Conference Poster
type: Anualidad
included: Medicina Clínica 2017
page start: 550

Autor:133301-Comunicación:184783
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: THE PROFILES OF PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO THEIR BELIEFS IN THEIR BIOLOGICAL DRUGS. ARCO STUDY

EULAR ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY
type: Entity
RO_0002234: THE PROFILES OF PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO THEIR BELIEFS IN THEIR BIOLOGICAL DRUGS. ARCO STUDY
type: Conference
type: BFO_0000015
type: BFO_0000003
type: Event
type: Thing
type: 2017
type: Anualidad

Medicina Clínica 2017
type: Anualidad
type: 2017
type: DepartmentReport
type: Thing
type: ResearchReport
includes: THE PROFILES OF PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO THEIR BELIEFS IN THEIR BIOLOGICAL DRUGS. ARCO STUDY